LymphoSign Inc. is a biopharmaceutical company developing novel proprietary therapeutics for the treatment cancer. The Company has developed a family of small molecules which target specific signal transduction pathways in cancer cells. The company's lead compounds have shown no toxicity in normal cells or tissues at several times therapeutic concentrations. The Company is targeting serious blood-related cancers, including leukemia, lymphoma and myeloma. These cancers are characterized by poor long-term remission and cure rates.
| Website | http://www.lymphosign.com |
| Revenue | $5.3 million |
| Employees | View employees |
| Address | 675 Cochrane Dr Fl 6, Markham, Ontario L3R 0B8, CA |
| Phone | (905) 530-2333 |
| Fax | (416) 964-6594 |
| Industry | Media & Internet General, Media & Internet |
| Competitors | Roche, Amgen, Bristol Myers Squibb, Thermo Fisher Scientific, Novartis, AbbVie, Genentech, Merck AH, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +46 more (view full list) |
| SIC | SIC Code 27 Companies, SIC Code 271 Companies |
| NAICS | NAICS Code 513 Companies, NAICS Code 51111 Companies, NAICS Code 5111 Companies, NAICS Code 51 Companies, NAICS Code 511 Companies, NAICS Code 511110 Companies |
Looking for a particular Lymphosign Inc. employee's phone or email?
Lymphosign Inc. Questions
The Lymphosign Inc. annual revenue was $5.3 million in 2026.
Lymphosign Inc. is based in Markham, Ontario.
The NAICS codes for Lymphosign Inc. are [513, 51111, 5111, 51, 511, 511110].
The SIC codes for Lymphosign Inc. are [27, 271].
